Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02709096
Recruitment Status : Completed
First Posted : March 15, 2016
Results First Posted : September 14, 2017
Last Update Posted : September 14, 2017
Sponsor:
Information provided by (Responsible Party):
BioPharmX, Inc.

Brief Summary:
This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1% Topical Gel (BPX-01) or BPX-01 Vehicle control.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: BPX-01, 1% Topical Gel Drug: BPX-01 Vehicle Gel Phase 2

Detailed Description:

The objective of this study is to evaluate the comparative reduction of Propionibacterium acnes (P. acnes) in-vivo following once daily topical administration of BPX-01 Minocycline 1% Topical Gel or BPX-01 Vehicle control Gel.

A secondary objective is to assess the tolerance of the treatment regimen versus a vehicle control. Safety laboratory data (chemistry and hematology) and plasma levels of minocycline are also of significant interest to the sponsor.

This is a single center, randomized, double blind, two-cell, vehicle controlled P. acnes study. All subjects will be randomized 2:1 to 1% BPX-01 or vehicle control to be applied as a topical gel once daily for four (4) weeks.

This is a six (6) week study with a four (4) week treatment period and a two (2) week post treatment follow up visit. The clinical endpoint is in-vivo quantification of P.acnes. The safety/tolerance endpoints are; observer reported: erythema, scaling-peeling, edema, and subject reported: tightness, burning-stinging, and itching. Plasma levels of minocycline and basic hematology and chemistry laboratory values will be collected.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes
Study Start Date : April 2016
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne

Arm Intervention/treatment
Experimental: BPX-01, 1% Topical Gel
BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
Drug: BPX-01, 1% Topical Gel
topical gel, applied to the forehead, cheeks, nose and chin
Other Name: BPX-01 Topical Gel

Placebo Comparator: BPX-01, Vehicle Gel
BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
Drug: BPX-01 Vehicle Gel
topical gel, applied to the forehead, cheeks, nose and chin
Other Name: BPX-01 Vehicle




Primary Outcome Measures :
  1. Logarithmic Change in Colony Counts of Facial Propionibacterium Acnes [ Time Frame: Cultures will be evaluated at Baseline, Week 1, Week 2, Week 4 and Week 6. Values reported at week 4 compared to baseline. ]
    P. Acnes cultures will be collected using the modified Kligman Method at each study visit. After plating, the samples will be cultured for 7 days and then evaluated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Be a healthy, adult male and/or female volunteer 18 to 40 years of age with no past or present history of any significant disease based on PI discretion;
  2. If female, must be post-menopausal, surgically sterile, or using effective birth control methods with a negative urine pregnancy test at the Screening and Baseline visits (female subjects of childbearing potential only);
  3. Show a high degree of fluorescence of the face under a Wood's lamp at the screening visit.
  4. Be willing to refrain from using antimicrobial topical products for the duration of study participation;
  5. Be willing to return to the study center for all study visits;
  6. Be willing to follow all study instructions and adhere to study restrictions;
  7. Provide informed consent to the study procedures and restrictions

Exclusion Criteria:

  1. Have a history of skin disease or presence of skin condition the PI believes would interfere with the study;
  2. Females who report that they are pregnant, planning a pregnancy or breastfeeding or those females who are of child bearing potential, that test positive with a urine pregnancy test;
  3. Have conditions or factors that the PI believes may affect the response of the skin or the interpretation of the results;
  4. Participated in any clinical study within the previous 30 days, be concurrently participating in other studies, or be involved in any aspect of test administration;
  5. Use of topical or systemic antibiotics or other products within the previous 4 weeks prior to baseline, that influence P. acnes counts;
  6. Are known to be allergic to any of the test product(s) or any components in the test product(s);
  7. Have a history of significant medical condition/disease that the PI believes may affect the response of the skin or the interpretation of the results;
  8. Has any other condition that, in the opinion of the Investigator or his designee, could interfere with the subject's ability to use the treatment as instructed, alter their treatment response, or affect their ability to complete the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02709096


Locations
Layout table for location information
United States, Pennsylvania
KGL Skin Study Center
Broomall, Pennsylvania, United States, 19008
Sponsors and Collaborators
BioPharmX, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Stuart Lessin, MD KGL, Inc.

Layout table for additonal information
Responsible Party: BioPharmX, Inc.
ClinicalTrials.gov Identifier: NCT02709096     History of Changes
Other Study ID Numbers: BPX-01-C02
First Posted: March 15, 2016    Key Record Dates
Results First Posted: September 14, 2017
Last Update Posted: September 14, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Minocycline
Anti-Bacterial Agents
Anti-Infective Agents